These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7587036)

  • 21. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
    Knothe H; Shah PM; Eckardt O
    Infection; 1991; 19(5):370-6. PubMed ID: 1800379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review and reassessment of dosing schedules for cefotaxime in selected medical indications.
    Young LS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):147-54. PubMed ID: 7587030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the use of cefotaxime in the treatment of skin and skin structure infections, with special reference to gram-positive pathogens.
    Karakusis PH; Trenholme GM; Levin S
    Infection; 1985; 13 Suppl 1():S46-9. PubMed ID: 4055055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of cefotaxime in healthy volunteers and patients.
    Patel KB; Nicolau DP; Nightingale CH; Quintiliani R
    Diagn Microbiol Infect Dis; 1995; 22(1-2):49-55. PubMed ID: 7587050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefotaxime and metronidazole in severe intra-abdominal infection.
    Aprahamian C; Schein M; Wittmann D
    Diagn Microbiol Infect Dis; 1995; 22(1-2):183-8. PubMed ID: 7587037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations.
    Wilson WR; Bouza E; Lode H; Mouton Y
    J Chemother; 1997 May; 9 Suppl 2():5-18. PubMed ID: 9248972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro activity of a new 3d-generation cephalosporin, cefodizime, on hospital bacteria].
    Soussy CJ; Otterbein G; Le Van Thoi J; Duval J; Chanal M; Cluzel M; Sirot D
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):561-6. PubMed ID: 3534743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
    Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G
    J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale for clinical trials evaluating ceftriaxone in the therapy of bacterial meningitis.
    Scheld WM; Rocha H; Sande MA; Bryan JP
    Am J Med; 1984 Oct; 77(4C):42-9. PubMed ID: 6093518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory and bactericidal activity of cefpirome and cefotaxime against blood culture isolates.
    Ansorg R; Primavesi CA; von Recklinghausen G
    Chemotherapy; 1990; 36(1):24-8. PubMed ID: 2106417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of third-generation cephalosporins. Anaerobes.
    Nichols RL; Smith JW
    Hosp Pract (Off Ed); 1991; 26 Suppl 4():11-7; discussion 48. PubMed ID: 1918210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.
    Jones RN; Erwin ME; Barrett MS; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(4):301-9. PubMed ID: 1889181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field].
    Toyonaga Y; Hatakeyama K; Yamori K; Sakaguchi N; Nakano K; Yamazaki M; Sugita M; Hori M
    Jpn J Antibiot; 1992 Jan; 45(1):48-73. PubMed ID: 1495196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Moxalactam and cefotaxime--two new beta-lactam antibiotics compared with three well-known cephalosporins].
    Baumgärtner M; Dickgiesser N; Müller S; Wundt W
    Arzneimittelforschung; 1981; 31(10):1677-81. PubMed ID: 6274361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
    Johnson DM; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of the clinical features of cefixime.
    Adam D
    Chemotherapy; 1998 Sep; 44 Suppl 1():1-5. PubMed ID: 9797415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cefotaxime (klaforan) in modern therapy of bacterial infections].
    Khess R; Budanov SV
    Antibiot Khimioter; 1996 Mar; 41(3):44-56. PubMed ID: 8967803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.